CNR1 and prostate carcinoma: To further characterize the signaling properties CBRs expressed in prostate cancer cells, experiments were next designed to determine whether chronic treatment with high-affinity CBR ligands would produce receptor downregulation in PC-3 and DU-145 cells similar to that occurring following prolonged treatment of cells expressing canonical CBRs (Figure 6).